Saykin, S
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
Ozempic may be an option for those individuals who are diabetic, have a body mass index (BMI) that is significantly over the healthy range (27 or above), have a weight-related disease, or have cardiovascular issues in addition to weight problems
The fix: give skin a few weeks before concluding anything, and see a dermatologist for persistent or spreading reactions
Dont leave pens in cars or near heat sources
HO-1, a critical antioxidant enzyme, enhances cellular defense against oxidative damage by catalyzing heme breakdown to produce Fe, carbon monoxide (CO), and biliverdin (35)